R-003 v1.0 | 2026-10-11 TREM2: when does it help, do little, or cause harm? AI-assisted targeted literature comparison; not peer reviewed Prioritize a state- and pathology-matched test of neuronal protection. Broad TREM2 activation has no established clinical benefit in the reviewed trial; no effective human subgroup or optimal dose is identified here. COMPARISONS Amyloid alone versus added tau Observed: The same murine agonist appears in a beneficial amyloid experiment and a harmful tau-seeding experiment. Interpretation: Tau context is a priority moderator to test, but age, dose and other design differences prevent a causal explanation from this pair alone. Sources: S9, S6 Timing is not a universal early-good / late-bad rule Observed: The harmful seeded experiment began before tau injection; a different antibody had favorable pathology findings when started in older amyloid mice. Interpretation: Stage must be defined by pathology and cell state, not age alone. The papers do not locate a human treatment window. Sources: S6, S10 Activation mode deserves a controlled comparison Observed: 03O05 increased sTREM2. The human AL002 trial lowered CSF sTREM2; acute AL002a experiments also reported increases. Interpretation: Do not collapse antibodies or soluble and membrane TREM2 into a simple good/bad rule. Shedding, signaling duration and brain exposure need matched measurements; higher sTREM2 is not itself proof of protection. Sources: S10, S6, S8 A cellular response is not a clinical success Observed: Functional rescue and expression-dependent metabolic responses coexist with a negative human efficacy trial. Interpretation: Select interventions by neuronal outcomes and safety, alongside target engagement, rather than treating a biomarker change as a therapeutic result. Sources: S1, S2, S3, S8 CONTEXT MATRIX C1 / S1 / Benefit in tested context level: Mouse / mechanism context: TREM2-deficient 5XFAD; impaired cellular energy handling intervention: Cyclocreatine metabolic support; not direct receptor agonism timing: Rescue experiment in a deficient amyloid model; regimen not fully extracted comparator: Deficient mice without metabolic rescue result: Improved microglial clustering and reduced plaque-adjacent neuritic dystrophy. limit: Rescuing a deficiency does not establish a benefit from increasing normal TREM2. No human cognitive outcome. location: Metabolic rescue results sample: Endpoint-specific biological replicate counts not extracted C2 / S2 / Benefit in tested context level: Human-derived cells context: iPSC-derived microglia carrying the R47H risk variant intervention: Manipulation of PPARγ / p38MAPK-related signaling timing: Cell-culture intervention; no clinical disease stage comparator: Variant and comparator cell conditions result: Metabolic switching and phagocytic function could be rescued. limit: A cellular functional result, not neuronal protection or patient benefit. Donor replication needs full-text verification. location: Indexed abstract sample: Donor and experiment counts not extracted C3 / S9 / Benefit in tested context level: Mouse / behavior context: Male 5XFAD amyloid model without added human tau seeds intervention: AL002a, 50 mg/kg intraperitoneally each week; MOPC control timing: Start at 4 months; 14 weeks of treatment; behavior during the final 2 weeks comparator: Isotype-matched MOPC; additional wild-type groups result: Less amyloid deposition and improved spatial learning and novel-object recognition. limit: One aggressive amyloid model; comparison with C6 also changes age, dose, sex composition and endpoints. location: Systemic administration; behavioral and chronic-treatment results sample: 5XFAD: 12 per antibody group; wild type: 8 AL002a, 7 control C4 / S10 / Benefit in tested context level: Mouse / pathology context: 5xFAD amyloid model; ligand-mimetic antibody 03O05 intervention: 30 mg/kg intraperitoneally weekly for 12 weeks timing: Start at 7 months; tissue 2 days after the final dose comparator: Vehicle-treated 5xFAD; age-matched wild type result: Higher soluble TREM2, fewer filamentous plaques and reduced neuronal dystrophy. limit: The disease experiment used vehicle rather than an isotype antibody control. No matched comparison proves superiority over other agonists or benefit in people. location: In vivo efficacy methods; Figures 3–6 sample: 14–15 mice per group in the chronic study C5 / S3 / Mixed / context-dependent level: Mouse / cell state context: APP SAA amyloid reporter mice; low, mid and high TREM2-expressing microglia intervention: Brain-penetrant ATV:4D9 versus isotype; 1 mg/kg monthly timing: Four doses at ages 8–11 months; collection at 12 months comparator: Isotype within expression strata result: Mid-expression cells showed increased metabolic indicators; low cells changed little; high cells showed attenuated or opposite responses. limit: These are metabolic profiles, not established benefit or injury. A high-expression response must not be labeled neuronal harm. Delayed collection limits acute-response interpretation. location: Figure 7 and chronic antibody-treatment methods sample: Assay-specific biological replicate counts not fully extracted C6 / S6 / Harm in tested context level: Mouse / amyloid + tau context: 5XFAD with human Alzheimer-derived tau injected at 6 months intervention: AL002a 80 mg/kg intraperitoneally weekly versus IgG timing: Start 1 week BEFORE tau injection; continue to 9 months comparator: Control IgG in the same seeded model result: More tau seeding/spreading and neuritic dystrophy; total amyloid burden did not fall. limit: Harm was not restricted to treatment after established tau pathology. Artificial seeding and other design differences prevent attribution to tau alone. location: Figure 1; chronic treatment and tau pathology results sample: Chronic groups: 27 antibody (13 female/14 male), 26 control (14 female/12 male); endpoint subsets vary C7 / S7 / No demonstrated benefit level: Mouse / AD models context: PS2APP and TauPS2APP; multiple agonist antibodies intervention: Para.09, mAb5 and mAb7 across separate designs timing: Early, middle and later treatment designs; 12- or 16-week regimens comparator: Matched experimental controls in each design result: Limited or no improvement in the tested Alzheimer-related pathological and neuronal endpoints. limit: A null finding is not proof of equivalence. CNS exposure, antibody format and timing remain possible explanations, not resolved causes. location: AD-model results and discussion sample: No single pooled n; full endpoint-level extraction pending C8 / S7 / Harm in tested context level: Mouse / demyelination context: Toxin-induced demyelination and repair models intervention: TREM2 agonist antibodies tested during injury/recovery timing: Repair-stage experiments; not a dementia clinical stage comparator: Experimental control treatment result: Recovery from demyelination was impaired in the tested settings. limit: A safety-context finding, not direct evidence of harm in human dementia. C7 and C8 are one publication, not independent replications. location: Demyelination results sample: Endpoint-specific n and regimens not fully extracted C9 / S4 / Benefit in tested context level: Mouse / ischemic injury context: Young adult male mice after transient bilateral carotid occlusion intervention: Lentiviral TREM2 overexpression timing: After 24-hour recovery; spatial learning assessed about 4 weeks later comparator: Injury/control-vector and sham conditions result: Better spatial-learning performance and hippocampal neuronal preservation. limit: Acute ischemia differs from aged vascular amyloid disease. Gene overexpression is not an antibody treatment. location: Animal groups, treatment and behavioral results sample: Three groups of 10; individual endpoint counts require verification C10 / S5 / Mixed / context-dependent level: Mouse / vascular amyloid context: CAA-prone Tg-SwDI mice; Trem2 wild type, heterozygous and knockout intervention: Lifelong genetic loss, not a timed treatment timing: Assessed at 16 months comparator: Different Trem2 genotypes in the same model result: Knockout reduced vascular amyloid but increased overall brain amyloid. limit: Opposing compartment outcomes are a trade-off. Knockout cannot be read backwards as proof that an agonist causes human vascular harm. location: Indexed abstract and Figure 1 descriptions sample: Figure 1 total amyloid: WT 7, heterozygous 7, knockout 6; not all endpoints C11 / S8 / No demonstrated benefit level: Human / randomized trial context: 381 participants with early Alzheimer’s disease intervention: AL002 15, 40 or 60 mg/kg IV every 4 weeks versus placebo timing: 48–96 weeks; primary estimate at week 96 comparator: Randomized, double-blind placebo control result: Target engagement without a significant primary CDR-SB benefit. MRI changes resembling ARIA were the most frequent reported treatment-emergent adverse events. limit: No established clinical efficacy for this regimen. Confidence intervals allow benefit and harm; adverse-event rates were not extracted from the subscription full text. location: Public abstract; NCT04592874 sample: 381 randomized across four groups NEXT RESEARCH 1. State-specific protection with a tau safety check Best next mechanistic question: when does functional microglial rescue coincide with less neuronal injury? Compare matched amyloid-only and amyloid-plus-tau conditions, stratify baseline TREM2 expression and functional impairment, and measure actual CNS exposure. Use neuronal injury as the prespecified primary endpoint; metabolism, tau spread and vascular injury are explanatory or safety endpoints. Advance only if neuronal protection replicates independently without a prespecified unacceptable increase in tau or vascular injury. A metabolic improvement alone does not pass. Priority hypothesis and proposed design; no experiment executed 2. Compare agonist mechanisms under matched conditions Binding epitope, shedding and signal duration could help explain conflicting outcomes; current comparisons are confounded. Compare ligand-mimetic and other agonist approaches with matched exposure, appropriate isotype controls, Fc characterization, membrane/soluble TREM2 measures and the same injury endpoints. Deprioritize the proposed mechanism if its predicted advantage disappears with matched controls or if soluble TREM2 shifts without neuronal protection. Exploratory mechanism; no validated superiority claim 3. Keep vascular and myelin outcomes as decision gates A favorable result in one tissue compartment may hide a worse result in another. Extract vessel-wall versus parenchymal amyloid, barrier injury and repair outcomes separately. First complete endpoint-level sample sizes, blinding, exclusions and uncertainty estimates. Do not interpret lower total amyloid or a repair biomarker as sufficient evidence of overall benefit. Required evidence work before selecting a translational candidate SOURCES S1 Ulland et al., Cell (2017) TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC5573224/ Access: Abstract and relevant full-text results S2 Piers et al., FASEB Journal (2020; online 2019) A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia https://pubmed.ncbi.nlm.nih.gov/31907987/ Access: Indexed abstract and publisher metadata S3 Feiten et al., Nature Communications (2026) TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism https://www.nature.com/articles/s41467-026-68706-8 Access: Relevant publisher full-text results, Figure 7 and dosing methods S4 Wang et al., Neural Plasticity (2020) TREM2 Overexpression Attenuates Cognitive Deficits in Experimental Models of Vascular Dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC7306072/ Access: Abstract, methods and relevant results S5 Loss of TREM2 / Tg-SwDI study, Alzheimer's & Dementia (2024) Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg-SwDI mice https://pubmed.ncbi.nlm.nih.gov/39308178/ Access: Indexed abstract and figure descriptions S6 Jain et al., Journal of Experimental Medicine (2023; online 2022) Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading https://rupress.org/jem/article/220/1/e20220654/213537/Chronic-TREM2-activation-exacerbates-A-associated Access: Abstract and relevant experimental results S7 Etxeberria et al., Journal of Neuroscience (2024) Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis https://pmc.ncbi.nlm.nih.gov/articles/PMC11255434/ Access: Abstract and relevant results/discussion S8 Mummery et al., Nature Medicine (2026) The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial https://www.nature.com/articles/s41591-026-04273-1 Access: Publisher abstract, public figure descriptions and disclosures; subscription full text not reviewed S9 Price et al., Journal of Neuroinflammation (2020) Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition https://link.springer.com/article/10.1186/s12974-020-01915-0 Access: Publisher full text: systemic administration, results and behavioral methods S10 Chen et al., Journal of Neuroinflammation (2026) A ligand-mimetic anti-TREM2 agonist antibody elevates soluble TREM2 and ameliorates pathology in mouse models of Alzheimer’s disease and multiple sclerosis https://link.springer.com/article/10.1186/s12974-026-03733-2 Access: Publisher full text: 5xFAD methods and results; antibody signaling and sTREM2 results CLINICAL ESTIMATES 15 mg/kg: -0.31 (95% CI -1.61 to 0.98) 40 mg/kg: 0.13 (95% CI -1.18 to 1.43) 60 mg/kg: -0.17 (95% CI -1.49 to 1.15) METHOD scope: Ten purposively selected primary publications; eleven context rows. Eight publications carried forward from R-002 plus two direct agonist comparators. This is a targeted narrative comparison, not a systematic review or meta-analysis. searchDate: 2026-10-11 retrieval: Follow-up of R-002 references and primary publisher/PubMed pages. Targeted searches concerned AL002a chronic activation, neutral/detrimental agonists, TREM2 expression-dependent metabolism and ligand-mimetic agonism. No exhaustive retrieval or screening denominator was recorded. classification: Benefit, no demonstrated benefit and harm refer only to the stated endpoints and experimental context. Mixed includes trade-offs and cellular responses with uncertain therapeutic meaning. Categories are not certainty grades. Papers and rows are not votes. limitations: Incomplete endpoint-level extraction, no formal risk-of-bias assessment, no pooled effects, no independent expert review and no reanalysis of underlying datasets. Missing sample sizes and regimens are explicitly marked. The trial subscription full text was not reviewed; several inherited records remain abstract-level. Funding and conflicts were not systematically compared. Access depth is listed per source. No exhaustive correction/retraction check is claimed. maintenance: Dated editorial report, separate from automatic publication scans. Future evidence changes require a versioned review. The website did not run new biological experiments or discover a validated therapeutic connection. nextDeliverable: A matched-comparison extraction sheet with all biological replicate counts, sex, dose/exposure, controls, blinding, exclusions and outcome uncertainties; followed by an independently reviewed protocol. No immediate human treatment experiment is proposed.